← boardnext 2027-03-31
ALT
Altimmune, Inc.distress 4/10 · elevated risk$2.77-1%today-55% from 52w high
Metabolic / Obesity 1
Lead: MASH · target GLP-1/GCG · est. market ~$5B (approx, global)
Revenue
pre-revenue
Liquidity
$332M
Runway
4.6 yrs
Shares 1y
+120%
Price & events
-48.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.4%
1D
-2.8%
1W
-4.8%
1M
-4.2%
3M
-49.6%
6M
-35.4%
1Y
-56.9%
2Y
-68.8%
5Y
-78.2%
All
Overview
- Market Cap
- $538.67M
- Enterprise Value
- $475.58M
- Volume
- 255.14K
- 52 Week Range
- $2.59 – $6.18
- Total Shares
- 194.47M
- Float Shares
- 164.20M
- Short %
- 24.52%
- % Held by Insiders
- 0.41%
- % Held by Institutions
- 58.07%
- RVOL
- 0.06x
- Beta
- 0.24
Pipeline stages · 1 programs
Pemvidutide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-03-31 Estimated 50% readout ~2027-05-15 | Phase 2 | Pemvidutide | Alcohol Liver Disease | — | recruiting |
| 2026-05 | Phase 2 | Pemvidutide | Alcohol Use Disorder (AUD) | 100 | active not recruiting |
| 2025-11-25 | Phase 2 | Pemvidutide | Non-Alcoholic Steatohepatitis (NASH) | 212 | completed |
Catalyst news & presentations · 7
- 2026-08-11Estimated 45%earningsEarningsEarnings releaseyahoo
- EASL 2026conferencedata presentationsecondaryPemvidutide · Phase 2b data presentation at EASL 2026PR wire
- before year endreadoutPhase 2pemvidutide · Report 48-week data including NIT and weight loss data from IMPACT Phase 2b trialSEC 8-K
- third quarter of 2025trial initiationsecondaryPhase 2pemvidutide · Phase 2 randomized, double-blind, placebo-controlled trial of ~100 subjects with obesity and ALD over 48 weeks.SEC 8-K
- second quarter of 2025trial initiationsecondaryPhase 2pemvidutide · Phase 2 randomized, double-blind, placebo-controlled trial of ~100 subjects with moderate to severe AUD over 24 weeks.SEC 8-K
- Q2 2025readoutPhase 2pemvidutide · Top-line data from IMPACT Phase 2b trial expected.SEC 8-K
- 2024-11-15conferencedata presentationsecondaryPhase 1pemvidutide · 12-week Phase 1b trial data presented at The Liver MeetingSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $15 (+458% upside) · 10 analysts
- 2026-06-22Leerink PartnersOutperform
- 2026-05-18HC Wainwright & Co.Buy
- 2026-05-14CitizensMarket Outperform
- 2026-03-16HC Wainwright & Co.Buy
- 2026-03-06B. Riley SecuritiesBuy
- 2025-11-07CitizensMarket Outperform
Competitors — GLP-1/GCG
- LLYELI LILLY & Co$1094.4B · D3
Recent news
- 2026-07-22ALT Stock Drops Pre-Market On Dilution Fears – Retail Calls It A ‘Horror Story’ - Stocktwits
- 2026-07-22Certain Common Stock of Altimmune, Inc. are subject to a Lock-Up Agreement Ending on 22-JUL-2026. - marketscreener.com
- 2026-07-15Attachment - GlobeNewswire
- 2026-07-13LULU, LCID, ALT Stocks Hit 52-Week Lows Today: What's Driving The Selloff? - Stocktwits
- 2026-07-07Altimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing Catalyst - Upgrade (ALT) - Seeking Alpha
- 2026-07-05Leerink Sees Altimmune (ALT) As An Attractive Play In The MASH Therapeutics Market - Yahoo Finance
- 2026-06-29Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
- 2026-06-29Altimmune, Inc.(NasdaqGM: ALT) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.